NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug – Newswise (press release)
|
NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug
Newswise (press release) Clinical trial research led by Arjun V. Balar, MD, of NYU Langone's Perlmutter Cancer Center, helped pave the way for the recent FDA approval of the immunotherapy drug atezolizumab as a first-line treatment for advanced bladder cancer. |
